BioLife Solutions (NASDAQ:BLFS) Director Amy Duross Sells 1,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $26.00, for a total value of $26,000.00. Following the transaction, the director directly owned 24,687 shares in the company, valued at $641,862. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amy Duross also recently made the following trade(s):

• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The shares were sold at an average price of $24.51, for a total value of $110,858.73.
• On Wednesday, November 19th, Amy Duross sold 477 shares of BioLife Solutions stock. The shares were sold at an average price of $24.50, for a total value of $11,686.50.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS traded up $2.33 during mid-day trading on Friday, hitting $26.53. The stock had a trading volume of 540,117 shares, compared to its average volume of 456,202. The business has a 50 day moving average price of $26.36 and a two-hundred day moving average price of $24.10. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.62. The firm has a market cap of $1.28 billion, a P/E ratio of -221.06 and a beta of 1.97.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.20.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of BLFS. Hantz Financial Services Inc. boosted its holdings in shares of BioLife Solutions by 54.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 659 shares during the last quarter. State of Wyoming lifted its position in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,490 shares during the period. Quarry LP grew its position in BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the period. US Bancorp DE grew its position in BioLife Solutions by 243.7% in the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,528 shares during the period. Finally, Ameritas Investment Partners Inc. raised its stake in BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.